Vaughan Nelson Investment Management, L.P. Adds $139M in Illumina, Inc. ($ILMN)

Vaughan Nelson Investment Management has taken a new position in Illumina, Inc. (NasdaqGS: ILMN), purchasing 863,721 shares. This acquisition is valued at approximately $139 million, according to the firm's latest Form 13F filing with the SEC. The move marks a fresh investment in the genetic sequencing company.

What Changed in Vaughan Nelson's Illumina Position

Vaughan Nelson Investment Management's move into Illumina, Inc. is a new buy, with the firm acquiring 863,721 shares. The shares, valued at $139 million as of the filing date, represent a significant new stake in the company, which previously had no shares held by the investment firm.

Other Institutional Activity in Illumina

Several other major funds have also adjusted their positions in Illumina. BlackRock, Inc. increased its holdings by 701,913 shares, bringing its total to 19,023,590 shares worth about $2.34 billion. Meanwhile, Capital World Investors reduced its position by 4,551,213 shares, leaving it with 15,549,960 shares valued at approximately $1.92 billion. Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both initiated positions with 6,823,654 and 6,594,836 shares, respectively, valued at about $841 million and $813 million. State Street Corp added 239,230 shares, ending with 6,429,344 shares worth around $792 million.

Illumina, Inc. Stock Snapshot

Shares of Illumina, Inc. (NasdaqGS: ILMN) recently traded around $160.97. The company boasts a market capitalization of approximately $24.35 billion and a P/E ratio of 29.2, indicating its valuation against earnings. Illumina's stock has fluctuated between a 52-week low of $86.03 and a high of $177.22. It maintains a 50-day moving average of $141.72 and a 200-day moving average of $125.43. The company's debt-to-equity ratio stands at 95.07, with a current ratio of 1.75 and a quick ratio of 1.23, reflecting its liquidity position.

Recent Earnings

In its latest financial results, Illumina reported revenue of $4.39 billion, with a modest growth rate of 4.8%. The company's net margin was 19.4%, and it achieved a return on equity of 33.8%. Illumina's earnings per share stood at $5.51. The next earnings release is scheduled for April 30, 2026.

Insider Buying and Selling at Illumina, Inc.

Recent insider activity at Illumina shows several planned sales. Patricia Leckman, SVP and Chief People Officer, sold 783 shares on June 5, 2026, and 784 shares on June 2, 2026, both as part of a pre-arranged 10b5-1 plan. Keith Meister sold 235,000 shares on June 1, 2026, outside of a planned sale, and 214,596 shares on May 29, 2026. Additionally, Scott Davies, Chief Legal Officer, and Scott Ericksen, VP and Chief Accounting Officer, each sold 615 and 500 shares, respectively, on May 29, 2026, under planned sales.

Analysts Set New Price Targets

On June 10, 2026, JP Morgan upgraded Illumina's stock to a 'buy' rating with a price target of $185. Guggenheim maintained its 'buy' rating with a $180 target on June 1, 2026. RBC Capital reinstated a 'buy' rating with a $170 target on May 15, 2026. Citigroup and Barclays maintained 'sell' ratings with targets of $95 and $122, respectively, earlier in May. Overall, the consensus recommendation is a 'buy', with a mean price target of $147.17 based on 18 analyst opinions.

About Illumina, Inc.

Illumina, Inc. is a healthcare company based in San Diego, California. It specializes in providing sequencing and array-based solutions for genetic and genomic analysis. The company serves a diverse range of customers, including genomic research centers, academic institutions, and healthcare providers. Under the leadership of CEO Jacob Thaysen, Illumina employs around 8,600 people and continues to innovate in the field of genetic research and diagnostics.

Bottom Line

Vaughan Nelson Investment Management's new stake in Illumina, Inc. highlights the firm's confidence in the company's growth prospects. With a market cap of over $24 billion and a broad range of institutional interest, Illumina remains a key player in the genetic sequencing industry. However, it's important to remember that 13F filings are backward-looking and may not reflect current positions. Investors often monitor such filings to gauge institutional sentiment and potential future performance.